Conditions: Carcinoma, Renal Cell
Keywords: sunitinib Phase IV metastatic renal cell carcinoma Chinese
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 105
Healthy volunteers: no

Brief summary:
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.

Detailed description:

Arms:
arm 1: single agent sunitinib, single arm

Interventions: intervention 1: Sunitinib Malate (SU011248)
Intervention descriptions: intervention 1: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.

Protocol document: